iBio, Inc. (IBIO): Nasdaq/NYSE listing notice — iBio receives Nasdaq deficiency notice for bid price below $1.00, has 180 days to cure

iBio, Inc.

Received Nasdaq notice on July 29, 2025 for failing Minimum Bid Price of $1.00 for 30 consecutive business days.
Company has until January 26, 2026 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.
If not cured, iBio may be eligible for additional 180 days if it meets other standards and notifies Nasdaq of intent to cure via reverse split.
No immediate effect on listing; stock continues trading on Nasdaq Capital Market under 'IBIO'.
Company intends to monitor bid price and consider options including reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

iBio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 29, 2025, iBio, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (June 13, 2025 to July 28, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”), as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-009992

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.